Fulcrum Therapeutics, Inc. (FULC) Targets Rare Disease

Fulcrum Therapeutics, Inc. (FULC) is a clinical-stage biopharmaceutical company focused on developing small-molecule therapies to treat genetically defined diseases. Its lead candidate, losmapimod, is being developed for facioscapulohumeral muscular dystrophy (FSHD), a rare and debilitating muscle disorder. Fulcrum’s growth is driven by advancing clinical trials, expanding its drug pipeline, and the growing interest in precision medicine targeting genetic conditions.

On the chart, a confirmation bar with rising volume indicates strong buying interest. The price has entered the momentum zone by moving above the .236 Fibonacci level. A trailing stop can be placed just below this level using the Fibonacci snap tool to protect profits while leaving room for further gains.